| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
5-HT receptor (antagonist); Dopamine receptor (antagonist)
|
|---|---|
| ln Vitro |
No specific in vitro assays for the impurity are provided. The non-degraded parent compound Ziprasidone is a combined 5-HT and dopamine receptor antagonist. Ziprasidone exhibits potent effects of antipsychotic activity by blocking serotonin 5-HT2A and dopamine D2 receptors. The amino acid open-ring impurity is less potent as a degradation product.
|
| ln Vivo |
Cellular activity data for the impurity are not specifically reported. The non-degraded Ziprasidone shows antagonist activity at 5-HT2A and dopamine D2 receptors in cell-based functional assays, inhibiting receptor-mediated signaling pathways including calcium mobilization and cAMP modulation, contributing to its antipsychotic efficacy.
|
| Enzyme Assay |
Standard radioligand binding assays are performed using membrane preparations from cells expressing human 5-HT2A or dopamine D2 receptors. [3H]-Ketanserin is used for 5-HT2A binding and [3H]-Spiperone for D2 binding. The test compound (Ziprasidone amino acid impurity) is incubated with membranes at varying concentrations. Bound radioligand is separated by filtration and counted by scintillation. Ki values are calculated via competition curves.
|
| Cell Assay |
Cell-based functional antagonist assays for 5-HT2A receptor are performed using HEK-293 cells stably expressing the receptor. Cells are loaded with calcium-sensitive fluorescent dye and treated with serial dilutions of the impurity. 5-HT (serotonin) is added to activate the receptor, and intracellular calcium increase is measured by fluorescence. Antagonist potency (IC50) is determined relative to Ziprasidone reference standard.
|
| Animal Protocol |
In vivo animal studies with the impurity are not typically performed as it serves as a reference standard for quality control rather than a therapeutic agent. Pharmacokinetic studies of Ziprasidone involve oral administration to rats or dogs, with blood and brain tissue collected at multiple time points. The impurity may be monitored as a degradation product in stability studies.
|
| ADME/Pharmacokinetics |
As an impurity reference standard, the compound is not intended for pharmacokinetic characterization in vivo. Analytical quantification of this impurity in Ziprasidone drug substance is performed by HPLC or LC-MS/MS using a validated method. It serves as a quality control marker to ensure pharmaceutical product purity and stability.
|
| Toxicity/Toxicokinetics |
As a reference standard for pharmaceutical analysis, Ziprasidone amino acid is not intended for therapeutic use and thus toxicology studies are not performed on this impurity. The parent drug Ziprasidone has an established clinical safety profile as an approved antipsychotic for schizophrenia and bipolar disorder, with known side effects including QT prolongation.
|
| References |
[1]. T F Seeger, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13.
|
| Additional Infomation |
Ziprasidone amino acid (Ziprasidone Impurity C) is an open-ring degradant formed under stress conditions. As a reference standard, it is critical for regulatory compliance in pharmaceutical manufacturing, ensuring that Ziprasidone drug product meets ICH guidelines for impurity limits. The parent drug Ziprasidone was first approved by the FDA in 2001.
|
| Molecular Formula |
C21H23CLN4O2S
|
|---|---|
| Molecular Weight |
430.95
|
| Exact Mass |
430.123
|
| CAS # |
1159977-64-6
|
| PubChem CID |
46783272
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.107
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
563
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CCN1CCC2=CC(=C(C=C2Cl)N)CC(=O)O)C3=NSC4=CC=CC=C43
|
| InChi Key |
VMQKWKNTSXIWGW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H23ClN4O2S/c22-17-13-18(23)15(12-20(27)28)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)29-24-21/h1-4,11,13H,5-10,12,23H2,(H,27,28)
|
| Chemical Name |
2-[2-amino-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-chlorophenyl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 20.83 mg/mL (48.34 mM)
DMSO: 4.81 mg/mL (11.16 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3205 mL | 11.6023 mL | 23.2045 mL | |
| 5 mM | 0.4641 mL | 2.3205 mL | 4.6409 mL | |
| 10 mM | 0.2320 mL | 1.1602 mL | 2.3205 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
